caa a22 4500 445334436 CHVBK 20180317142749.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1245/s10434-011-1731-2 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1731-2 Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis [Elektronische Daten] [Daniel Sargent, Murray Resnick, Michael Meyers, Atoussa Goldar-Najafi, Thomas Clancy, Sharlene Gill, Gary Siemons, Qian Shi, Brian Bot, Tsung-Teh Wu, Guillaume Beaudry, Jean-François Haince, Yves Fradet] Purpose: The prognostic significance of guanylyl cyclase C (GCC) gene expression in lymph nodes (LNs) was evaluated in patients with stage II colon cancer who were not treated with adjuvant chemotherapy. We report a planned analysis performed on 241 patients. Methods: GCC mRNA was quantified by RT-qPCR using formalin-fixed LN tissues from patients with untreated stage II colon cancer who were diagnosed from 1999-2006 with at least ten LNs examined and blinded to clinical outcomes. Lymph node ratio (LNR) is the number of GCC-positive nodes divided by total number of informative LNs. Risk categories of low (0-0.1) and high (>0.1) for LNR were chosen by significance using Cox regression models. The data were tested for association with time to recurrence. Results: Twenty-nine patients (12%) had a disease recurrence or cancer death. The LNR significantly predicted higher recurrence risk for 84 patients (34.9%) classified as high risk (hazard ratio (HR), 2.38; P=0.02). The estimated 5-year recurrence rates were 10% and 27% for the low- and high-risk groups, respectively. After adjusting for age, T stage, number of nodes assessed, and MMR status, a significant association remained (HR, 2.61; P=0.02). In a subset of patients (n=181) with T3 tumor,≥12 nodes examined and negative margins, a significant association between the GCC LNR and recurrence risk also was observed (HR, 5.06; P=0.003). Conclusions: Our preliminary results suggest that detection of GCC mRNA in LNs is associated with risk of disease recurrence in patients with untreated stage II colon cancer. A larger validation study is ongoing. Society of Surgical Oncology, 2011 Sargent Daniel Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA aut Resnick Murray Alpert Medical School, Brown University and Rhode Island Hospital, Providence, RI, USA aut Meyers Michael Division of Surgical Oncology, The University of North Carolina, Chapel Hill, NC, USA aut Goldar-Najafi Atoussa Department of Pathology, Lahey Clinic Gordon Cancer Center, Burlington, MA, USA aut Clancy Thomas Division of Surgical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA aut Gill Sharlene Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada aut Siemons Gary Colon and Rectal Surgical Associates of South Jersey, Voorhees, NJ, USA aut Shi Qian Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA aut Bot Brian Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA aut Wu Tsung-Teh Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA aut Beaudry Guillaume DiagnoCure Inc, Québec, QC, Canada aut Haince Jean-François DiagnoCure Inc, Québec, QC, Canada aut Fradet Yves DiagnoCure Inc, Québec, QC, Canada aut Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3261-3270 1068-9265 18:12<3261 2011 18 10434 https://doi.org/10.1245/s10434-011-1731-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1731-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sargent Daniel Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA aut NATIONALLICENCE 700 1- Resnick Murray Alpert Medical School, Brown University and Rhode Island Hospital, Providence, RI, USA aut NATIONALLICENCE 700 1- Meyers Michael Division of Surgical Oncology, The University of North Carolina, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Goldar-Najafi Atoussa Department of Pathology, Lahey Clinic Gordon Cancer Center, Burlington, MA, USA aut NATIONALLICENCE 700 1- Clancy Thomas Division of Surgical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA aut NATIONALLICENCE 700 1- Gill Sharlene Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada aut NATIONALLICENCE 700 1- Siemons Gary Colon and Rectal Surgical Associates of South Jersey, Voorhees, NJ, USA aut NATIONALLICENCE 700 1- Shi Qian Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA aut NATIONALLICENCE 700 1- Bot Brian Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA aut NATIONALLICENCE 700 1- Wu Tsung-Teh Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA aut NATIONALLICENCE 700 1- Beaudry Guillaume DiagnoCure Inc, Québec, QC, Canada aut NATIONALLICENCE 700 1- Haince Jean-François DiagnoCure Inc, Québec, QC, Canada aut NATIONALLICENCE 700 1- Fradet Yves DiagnoCure Inc, Québec, QC, Canada aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3261-3270 1068-9265 18:12<3261 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer